Functional Analysis of Viable Circulating Tumor Cells from Triple-Negative Breast Cancer Patients Using TetherChip Technology.
EMT
circulating tumor cells
immune checkpoints
metastasis
triple-negative breast cancer
vinorelbine
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
26 07 2023
26 07 2023
Historique:
received:
23
06
2023
revised:
14
07
2023
accepted:
24
07
2023
medline:
14
8
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
epublish
Résumé
Metastasis, rather than the growth of the primary tumor, accounts for approximately 90% of breast cancer patient deaths. Microtentacles (McTNs) formation represents an important mechanism of metastasis. Triple-negative breast cancer (TNBC) is the most aggressive subtype with limited targeted therapies. The present study aimed to isolate viable circulating tumor cells (CTCs) and functionally analyze them in response to drug treatment. CTCs from 20 TNBC patients were isolated and maintained in culture for 5 days. Biomarker expression was identified by immunofluorescence staining and VyCap analysis. Vinorelbine-induced apoptosis was evaluated based on the detection of M30-positive cells. Our findings revealed that the CTC absolute number significantly increased using TetherChips analysis compared to the number of CTCs in patients' cytospins (
Identifiants
pubmed: 37566019
pii: cells12151940
doi: 10.3390/cells12151940
pmc: PMC10416943
pii:
doi:
Substances chimiques
Vinorelbine
Q6C979R91Y
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : R01 CA154624
Pays : United States
Références
Breast Cancer Res. 2011 Jun 10;13(3):R59
pubmed: 21663619
Cancers (Basel). 2021 Apr 29;13(9):
pubmed: 33947159
Cancers (Basel). 2023 Jan 31;15(3):
pubmed: 36765843
J Natl Compr Canc Netw. 2018 Mar;16(3):310-320
pubmed: 29523670
Nat Rev Clin Oncol. 2019 Mar;16(3):185-204
pubmed: 30514977
Cancer Res. 2015 Jan 1;75(1):203-15
pubmed: 25503560
Mol Cancer Ther. 2013 Sep;12(9):1886-95
pubmed: 23778153
Int J Dev Biol. 2022;66(1-2-3):277-283
pubmed: 34881791
Cancer Res. 2008 Jul 15;68(14):5678-88
pubmed: 18632620
Cancers (Basel). 2023 Mar 25;15(7):
pubmed: 37046635
Breast Cancer Res Treat. 2011 Oct;129(3):691-701
pubmed: 21069453
Cancer Discov. 2021 Apr;11(4):858-873
pubmed: 33811121
Oncotarget. 2015 Oct 20;6(32):33972-81
pubmed: 26378017
Cancer Res. 2015 Mar 1;75(5):892-901
pubmed: 25592149
Cell Syst. 2019 Aug 28;9(2):109-127
pubmed: 31465728
Pharmacol Ther. 2022 Sep;237:108253
pubmed: 35872332
Mol Med. 2007 Jan-Feb;13(1-2):79-88
pubmed: 17515959
J Pers Med. 2022 Jan 25;12(2):
pubmed: 35207643
Oncol Lett. 2018 Feb;15(2):2635-2640
pubmed: 29434985
Nature. 2016 Jan 21;529(7586):298-306
pubmed: 26791720
Eur J Cell Biol. 2006 Apr;85(3-4):213-8
pubmed: 16546563
Breast Cancer Res Treat. 2014 Jul;146(1):15-24
pubmed: 24842267
J Cancer. 2016 Apr 10;7(7):784-93
pubmed: 27162536
Clin Cancer Res. 2004 Dec 15;10(24):8152-62
pubmed: 15623589
Breast Cancer Res. 2022 Feb 14;24(1):13
pubmed: 35164808
Exp Cell Res. 2007 Apr 15;313(7):1326-36
pubmed: 17359970
Cancer Res. 2010 Oct 15;70(20):8127-37
pubmed: 20924103
Lab Chip. 2020 Aug 21;20(16):2872-2888
pubmed: 32744284
Oncotarget. 2017 Jan 17;8(3):5309-5322
pubmed: 28029660
Oncogene. 2010 Jun 3;29(22):3217-27
pubmed: 20228842
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Pharmacol Res. 2020 Mar;153:104683
pubmed: 32050092
Front Oncol. 2014 Jun 18;4:153
pubmed: 24995158
Cancer Res. 2014 Feb 15;74(4):1250-60
pubmed: 24371229
Cancer Drug Resist. 2021;4(3):517-542
pubmed: 34888495
Breast Cancer Res. 2018 Jul 5;20(1):67
pubmed: 29976237
Oncologist. 2021 Oct;26(10):827-834
pubmed: 34176192
Breast Cancer Res. 2008;10(5):R80
pubmed: 18822183
Clin Chem. 2020 Aug 1;66(8):1093-1101
pubmed: 32712650
Oncogene. 2010 Dec 2;29(48):6402-8
pubmed: 20956943